Molecular Pharmaceutics

Molecular Pharmaceutics is a monthly peer-reviewed journal of the American Chemical Society, founded in 2004 and centred on the molecular mechanisms of drug delivery and drug delivery systems, with a 2025 Journal Impact Factor of 4.9.《分子药剂学》（Molecular Pharmaceutics）由美国化学会（American Chemical Society）出版，2004 年创刊，月刊，聚焦药物递送与递送体系的分子机制，2025 年期刊影响因子为 4.9。

Scope

• The journal publishes original theoretical and experimental work that significantly advances the molecular mechanistic understanding of drug delivery and drug delivery systems.刊物发表理论与实验原创研究，要求对药物递送及递送体系的分子机制有实质推进。
• Modalities covered include small molecules, imaging agents, proteins, peptides, vaccines, and cell- and gene-based therapies, together with their characterization, formulation and delivery.覆盖的模态包括小分子、显像剂、蛋白质、多肽、疫苗以及细胞与基因治疗产品，并涉及其表征、制剂与递送。
• Modelling and simulation are used to generate mechanistic insight into delivery processes.刊物以建模与模拟获得对递送过程的机制性认识。
• A second strand is the molecular understanding of formulations and their performance under physiological conditions.另一条主线是制剂及其在生理条件下表现的分子层面理解。
• Materials science is considered as it bears on the efficacy of drugs, excipients and delivery systems.材料科学则围绕其与药物、辅料及递送体系有效性的关系展开。
• Emerging techniques and technologies fall within scope, including theranostics, precision medicine and artificial intelligence.新兴技术与方法亦在范围之内，包括诊疗一体化、精准医学与人工智能。
• Accepted contributions appear as Articles, Communications, Perspectives and Reviews, with work at the interface of drug discovery and development particularly encouraged.录用稿件以论文、通讯、视角与综述形式发表，尤其鼓励处于药物发现与开发交界处的研究。

History

• The journal was launched by the American Chemical Society in 2004, with volume 1, issue 1 dated January/February 2004.刊物由美国化学会于 2004 年创办，第 1 卷第 1 期标注为 2004 年 1 至 2 月。
• Gordon L. Amidon of the University of Michigan College of Pharmacy was the founding Editor-in-Chief and wrote the opening editorial.创刊主编为密歇根大学药学院（University of Michigan College of Pharmacy）的（Gordon L. Amidon），他同时撰写开篇社论。
• It appeared bimonthly at first and became monthly in 2012, when volume 9 carried twelve issues instead of six.刊物最初为双月刊，2012 年第 9 卷起改为月刊，每年出版 12 期而非 6 期。
• Amidon led the title until 2019, when Lynne S. Taylor of Purdue University was appointed as his successor.此后（Amidon）执掌刊物至 2019 年，再由普渡大学（Purdue University）的（Lynne S. Taylor）接任。
• Its twentieth anniversary was marked by a joint editorial reviewing two decades of the journal.创刊二十周年时，刊物以一篇联合社论回顾了二十年历程。^[1]
• The 2025 Journal Impact Factor is 4.9, following 4.5 in 2024, 5.364 in 2022 and 4.939 in 2021.2025 年期刊影响因子为 4.9，此前 2024 年为 4.5，2022 年为 5.364，2021 年为 4.939。
• Content is indexed in SCIE, Scopus and PubMed/MEDLINE, and articles may be published open access under CC BY or CC BY-NC-ND licences.刊物被 SCIE、Scopus 与 PubMed/MEDLINE 收录，论文可按 CC BY 或 CC BY-NC-ND 许可开放获取。

Editors

• The Editor-in-Chief is Lynne S. Taylor, Retter Professor of Pharmacy at Purdue University, whose work concerns amorphous solid dispersions, crystallization and the physical stability of formulations.现任主编为（Lynne S. Taylor），普渡大学（Purdue University）药学讲席教授（Retter Professor of Pharmacy），研究无定形固体分散体、结晶与制剂的物理稳定性。
• Associate editors include Christel Bergstrom at Uppsala University in Sweden, who works on in silico and in vitro prediction of drug absorption.副编辑包括瑞典乌普萨拉大学（Uppsala University）的（Christel Bergstrom），研究方向为药物吸收的计算机与体外预测。
• Afsaneh Lavasanifar at the University of Alberta in Canada and Raj Suryanarayanan at the University of Minnesota in the United States cover nanomedicine and pharmaceutical materials respectively.加拿大阿尔伯塔大学（University of Alberta）的（Afsaneh Lavasanifar）与美国明尼苏达大学（University of Minnesota）的（Raj Suryanarayanan）分别负责纳米医学与药物材料方向。
• Kristofer Thurecht at the University of Queensland in Australia completes the senior editorial group, which draws on North America, Europe, Asia and Australia.澳大利亚昆士兰大学（University of Queensland）的（Kristofer Thurecht）亦在资深编辑团队之列，团队覆盖北美、欧洲、亚洲与澳洲。
• Manuscripts are handled through single-anonymized peer review, in which reviewers know author identities but authors do not know reviewer identities.稿件采用单盲评审，审稿人知晓作者身份，作者不知审稿人身份。
• Submissions go through the ACS Publishing Center, and no pre-submission enquiry is required.投稿经（ACS Publishing Center）提交，无需事先询问编辑。